ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

9:00AM-10:30AM: Abstract Number: 1646

A Novel E3 Ligase of GILZ: Validation of a Steroid-sparing Therapeutic Target in SLE

Plenary II

9:00AM-10:30AM: Abstract Number: 1642

A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus Nephritis

Plenary II

9:00AM-10:30AM: Abstract Number: 1645

Antisynthetase Autoantibodies Disrupt the Function of Their Target Aminoacyl-tRNA Synthetases in Muscle Cells

Plenary II

9:00AM-10:30AM: Abstract Number: 1647

Improved Fertility in Women with Rheumatoid Arthritis and a Wish to Conceive When Treated According to a Treat-to-target Approach Aimed at Remission

Plenary II

9:00AM-10:30AM: Abstract Number: 1644

RISE Registry Associated with Significant Gains in Quality Measure Performance: An InterruptedTimes Series Analysis Before and After Participation

Plenary II

9:00AM-10:30AM: Abstract Number: 1643

Single Nuclei Multiome and Spatial Transcriptomic Analysis of Early, Untreated SSc Skin Identifies Signaling Interactions Between Macrophages and Fibroblasts

Plenary II

10:30AM-12:30PM: Abstract Number: 1574

Therapeutic Strategy in Patients with Mixed Connective Tissue Disease: A Multicenter Retrospective Study in the French MCTD Cohort

Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1311

“A Fellow-Driven Voluntary Initiative in Musculoskeletal Ultrasound Training: Interest Does Not Equal Attendance”

Professional Education Poster

10:30AM-12:30PM: Abstract Number: 1622

18F-FDG PET/CT in LVV During Active and Inactive Disease Phases Is Associated with the Metabolic Profile, but Not with Macrophage-related Cytokines: Results of an Integrated Analysis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1113

2nd Analysis of IgG4-Related Disease in a Diverse Long Island Population: Utilizing Serological and Histological Markers for Assessing Treatment Response

Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1072

A 2-Year Pilot Project to Identify and Address Disparities in Health Literacy in Patients with Rheumatic Diseases Through Distribution of Surveys and Patient Education Materials

Measures & Measurement of Healthcare Quality Poster

10:30AM-12:30PM: Abstract Number: 0898

A Blood Transcriptome Signature Distinguishes Between Diverse Systemic Autoimmune Diseases and Infection

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 1306

A Comparative Analysis of ChatGPT-4, Microsoft’s Bing and Google’s Bard at Answering Rheumatology Clinical Questions

Professional Education Poster

10:30AM-12:30PM: Abstract Number: 0951

A Feedback Loop Involving mtDNA, Platelets and Neutrophil Extracellular Traps Amplifies Inflammation in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Basic Science Poster I

10:30AM-12:30PM: Abstract Number: 1399

A First-in-Human Clinical Trial Evaluating the Safety and Pharmacokinetics of SOL-116, a Novel Humanized Monoclonal Antibody Targeting Bile Salt-Stimulated Lipase for the Treatment of RA

RA – Treatment Poster II

1
2
3
…
59
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].